Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
Key Highlights
- ➤1,379 Impella-supported HRPCI patients showed lower mortality than CHIP-BCIS3 reports
- ➤279-patient TRI-GUARD-PCI registry reported 30-day mortality of 6.1%
- ➤522-patient U.S. registry found 3.4% cardiovascular mortality at discharge
- ➤578 PROTECT III patients had 4.7% in-hospital mortality versus CHIP-BCIS3’s ~8%
- ➤PROTECT IV randomized trial results are anticipated in 2027
Expert Statements
Navin Kapur, M.D., Chief medical and scientific officer, Heart Recovery, MedTech, Johnson & Johnson
“Data from these high-impact presentations add to more than two decades of evidence supporting Impella use in complex HRPCI patients”
Navin Kapur, M.D., Chief medical and scientific officer, Heart Recovery, MedTech, Johnson & Johnson
“They also reinforce that outcomes depend not only on the device but how and when it is used, from selecting the right patients and procedural approach to post-procedural management and critical care.”
Matthias Bossard, M.D., Interventional cardiologist and researcher, Dalhousie University
“These real-world results provide important insights into outcomes following Impella-supported high-risk PCI in contemporary clinical practice,”
Matthias Bossard, M.D., Interventional cardiologist and researcher, Dalhousie University
“The findings may help inform patient selection and procedural planning for complex high-risk interventions.”
Vasileios Panoulas, M.D., Physician at Royal Brompton and Harefield Hospitals in London
“This analysis provides real-world perspective on the use of Impella during HRPCI and highlights differences from the CHIP-BCIS3 study protocol,”
Vasileios Panoulas, M.D., Physician at Royal Brompton and Harefield Hospitals in London
“These observations suggest a potential relationship between duration of support, post-procedural management and patient outcomes,”
Vasileios Panoulas, M.D., Physician at Royal Brompton and Harefield Hospitals in London
“In the high-risk PROTECT III cohort, Impella-supported HRPCI was performed in patients with severe left ventricular dysfunction and complex coronary anatomy, including frequent left main and multivessel treatment, with lower mortality rates than reported in CHIP-BCIS3,”
Vasileios Panoulas, M.D., Physician at Royal Brompton and Harefield Hospitals in London
“Understanding mortality after HRPCI requires looking at patient risk at baseline, procedural complexity and the importance of post-procedure patient management.”
Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
Analyses presented at TCT highlight how patient selection, timely Impella support and consistent care protocols may help improve outcomes during and after complex heart procedures
Get started
Create a free account to read the full story.